Cancer patients should be regularly tested for thromboembolic risk upon starting chemotherapy, according to guidelines from the American Society of Clinical Oncology that are published in the Journal of Clinical Oncology. The group recommended low-molecular-weight heparin for prophylaxis. Newer oral anticoagulants should not be administered in patients with malignancy.

Related Summaries